For the Inventor, By the Inventor

Enter assignee name

Lexington, MA, United States of America

Keros Therapeutics, Inc.

USPTO Granted Patents = 15

EPO Patents = 2

Trademarks = 4

Forward Citations = 31

Loading Chart...

Loading Chart...

8 inventors (with patents filed for the assignee):

Jennifer Lachey (14 out of 19 patents)

Jasbir S Seehra (14 out of 110 patents)

Elissa Furutani (2 out of 2 patents)

4. Catherine Anne Evans (1 out of 44 patents)

5. Claudia Ordonez (1 out of 1 patent)

6. Sarah Bethune (1 out of 1 patent)

7. Krista Diaz (1 out of 1 patent)

8. Christopher R Rovaldi (1 out of 1 patent)

15 patents: Sort by Forward Citations

1. 12508262 - Methods of using ALK2 inhibitors (2025-12-30),

2. 12458693 - Methods of treating iron overload with a BMP inhibitor (2025-11-04),

3. 12440539 - Methods of using activin receptor type IIB variants (2025-10-14),

4. 12404313 - GDNF fusion polypeptides and methods of use thereof (2025-09-02),

5. 12364737 - Activin receptor type IIA variants and methods of use thereof (2025-07-22),

6. 12350313 - Activin receptor type IIa variants and methods of use thereof (2025-07-08),

7. 12331124 - ALK2 antibodies and methods of use thereof (2025-06-17),

8. 12269858 - Activin receptor type IIB variants and methods of use thereof (2025-04-08),

9. 12071438 - Crystal forms of an ALK2 inhibitor (2024-08-27),

10. 11912750 - GDNF fusion polypeptides and methods of use thereof (2024-02-27),

11. 11884715 - Activin receptor type IIB variants and methods of use thereof (2024-01-30),

12. 11717558 - Nucleic acid molecules encoding activin receptor type IIA variants (2023-08-08),

13. 11484573 - Activin receptor type IIa variants and methods of use thereof (2022-11-01),

14. 11090361 - Activin receptor type IIa variants and methods of use thereof (2021-08-17),

15. 11013785 - Activin receptor type IIA variants and methods of use thereof (2021-05-25),

Keros Therapeutics is a clinical-stage biotechnology company focused on developing therapies for hematological, musculoskeletal, and other diseases. Their lead candidates target specific protein interactions to modulate signaling pathways involved in disease progression. With a team of experienced researchers and industry experts, Keros Therapeutics is committed to addressing unmet medical needs and advancing innovative treatments to improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

15 Patents

#48 in Lexington, MA

#1,231 in Massachusetts

#20,443 in US

#38,742 in the World

Lexington, MA, United States of America

Keros Therapeutics, Inc.

Forward Citations = 31

8 inventors:

Jennifer Lachey (14 out of 19 patents)

Jasbir S Seehra (14 out of 110 patents)

Elissa Furutani (2 out of 2 patents)

4. Catherine Anne Evans (1 out of 44 patents)

5. Claudia Ordonez (1 out of 1 patent)

Please report any incorrect information to support@idiyas.com

Loading…